ARDS Prediction Score in Critically Ill Patients in China

Septic Shock Clinical Trial

Official title:

ARDS Prediction Score in Critically Ill Patients in China

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02174081
• Other study ID #: ARDS Prediction system
• Status: Completed
• Phase: N/A
• First received: June 11, 2014
• Last updated: June 27, 2016
• Start date: March 2014
• Est. completion date: June 2016

Study information

• Verified date: June 2016
• Source: Southeast University, China
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Ministry of Health
• Study type: Observational

Clinical Trial Summary

ARDS is a severe disease, it's important to predict the incidence of ARDS.

Description:

From January 1 to January 31, 2012 and from January 1 to January 10, 2013 , all patients admit to the ICUs will be enrolled. The demographic characteristics, diagnosis, formerly medical history, Ventilator indications, Ventilator data, other respiratory treatments, weaning outcome and 28 day mortality will be recorded.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 698
• Est. completion date: June 2016
• Est. primary completion date: March 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

Critically ill patients who admitted into participating ICU

Exclusion Criteria:

Patients with chronic pulmonary disease such as chronic obstructive pulmonary disease (COPD), asthma, lung cancer, pulmonary fibrosis and tuberculosis Age less than 18 years old Pregnancy Died within 24 hours from ICU admission ARDS patients who diagnosed 24hours before ICU admission Referral from other hospital to participating ICU Lack of data of ARDS risk factors

Study Design

Observational Model: Cohort

Related Conditions & MeSH terms

• ARDS
• Critical Illness
• Septic Shock

Locations

Country	Name	City	State
China	Zhongda Hospital	Nanjing	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Jianfeng Xie

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	incidence of ARDS	evaluate the incidence of risk factors of ARDS	up to 24 months	Yes